Enveric Biosciences, Inc. (ENVB)
|Net Income (ttm)||-7.28M|
|Trading Day||January 26|
|Day's Range||4.03 - 4.41|
|52-Week Range||2.62 - 14.80|
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Enveric Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...
NAPLES, Fla., Jan. 15, 2021 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines ...
Ameri Holdings Completes Spin-Off and Tender Offer, Changes Name to Enveric Biosciences and Begins Trading on the Nasdaq Under the Symbol "ENVB"
NAPLES, Fla., Dec. 31, 2020 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), formerly AMERI Holdings, Inc. (NASDAQ: AMRH), a patient-centric biotechnology...
Jay Pharma develops evidence-based cannabinoid products and combination therapies cure effects of cancer treatment. The company was incorporated in 2017 and is based in Toronto, Canada.
|Stock Exchange |
|Ticker Symbol |
In 2019, ENVB's revenue was $39.91 million, a decrease of -7.17% compared to the previous year's $43.00 million. Losses were -$5.61 million, -66.81% less than in 2018.